Cline Christopher's Insider Trades & SAST Disclosures
Cline Christopher's most recent trade in Travere Therapeutics Inc was a trade of 4,920 Common Stock done . Disclosure was reported to the exchange on May 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Cline Christopher.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 94,910 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 4,920 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 02 May 2025 | 1,784 | 93,126 (0%) | 0% | 21.0 | 37,553 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 13.15 per share. | 11 Apr 2025 | 48 | 89,990 (0%) | 0% | 13.1 | 631 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 58,000 | 58,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 21,500 | 95,230 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.12 per share. | 31 Jan 2025 | 5,192 | 90,038 (0%) | 0% | 20.1 | 104,463 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 18.94 per share. | 22 Jan 2025 | 865 | 73,730 (0%) | 0% | 18.9 | 16,384 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 6,750 | 77,085 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 05 Sep 2024 | 2,490 | 74,595 (0%) | 0% | 11.5 | 28,685 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 04 Sep 2024 | 514 | 70,335 (0%) | 0% | 9.5 | 4,888 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.74 per share. | 11 Apr 2024 | 54 | 70,849 (0%) | 0% | 6.7 | 364 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 65,000 | 65,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Cline Christopher | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 25,000 | 74,721 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 3,818 | 70,903 (0%) | 0% | 8.5 | 32,573 | Common Stock |
| Travere Therapeutics Inc | Cline Christopher | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 9.07 per share. | 23 Jan 2024 | 853 | 49,721 (0%) | 0% | 9.1 | 7,735 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.59 per share. | 10 May 2023 | 455 | 51,031 (0%) | 0% | 16.6 | 7,548 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.49 per share. | 11 Apr 2023 | 47 | 51,486 (0%) | 0% | 21.5 | 1,010 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 54,500 | 54,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 20,250 | 53,121 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 6,750 | 6,750 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.75 per share. | 31 Jan 2023 | 1,588 | 51,533 (0%) | 0% | 21.8 | 34,542 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.90 per share. | 24 Jan 2023 | 852 | 32,871 (0%) | 0% | 21.9 | 18,663 | Common Stock |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 48,000 | 48,000 | - | - | Employee Stock option (right to buy) | |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 9,840 | 9,840 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Christopher Cline | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 5,000 | 33,723 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges